Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction
Open Access
- 17 September 2022
- journal article
- research article
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 28 (12) , 1673-1682
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection FractionJAMA, 2019
- Initiation of Sacubitril/Valsartan in Haemodynamically Stabilised Heart Failure Patients in Hospital or Early After Discharge: Primary Results of the Randomised TRANSITION StudyEuropean Journal of Heart Failure, 2019
- B-Type Natriuretic Peptide During Treatment With Sacubitril/ValsartanJACC, 2019
- Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart FailureNew England Journal of Medicine, 2019
- Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of EchocardiographyJournal of the American Society of Echocardiography, 2019
- Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF)American Heart Journal, 2018
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of AmericaCirculation, 2017
- Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart FailureCirculation, 2015
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- Pathological Ventricular RemodelingCirculation, 2013